Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Eugit Therapeutics logo — Tissue targeting of therapies

Eugit Therapeutics

Tissue targeting of therapies

Founded 2022 United States San Carlos, United States 2 employees Seed Total: $130.00K Biotechnology, Health Care +1

General Information

Company Name Eugit Therapeutics
Founded Year 2022
Location United States San Carlos, United States
Employees 2
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Business Model B2B, B2D
Revenue Model Licensing, Service Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Eugit Therapeutics. To contact Eugit Therapeutics, visit eugittx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Eugit Therapeutics compare?

A PDF of Eugit Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Eugit Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Eugit Therapeutics

Eugit Therapeutics, with its compelling slogan "Tissue targeting of therapies," emerges as an innovative player in the Biotechnology sector. Established in 2022 and based in the United States, this startup is cofounded by renowned academic George Church of Harvard. Their prominent backing includes Y Combinator, part of their S22 cohort, and a significant NSF Ph1 grant.

Positioned at the intersection of Health Care and Wellness, Eugit Therapeutics secured a $130.00K Seed investment on 01 September 2022, highlighting their potential for growth and innovation within their field.

With experienced leadership and strategic partnerships, Eugit Therapeutics presents a strong case for investors interested in cutting-edge biotech advancements. Their targeted approach to therapy delivery holds promise for significant impacts in healthcare.

Business keywords: Tissue Targeting Therapies, Immune System, Drug Discovery, Immune-Mediated Diseases, Inflammatory Bowel Disease, IBD, Gamma Delta T Cells, Precision Medicine, Therapeutic Development, Biomedical Innovation, Harvard Co-Founded, Y Combinator Backed, NSF Funded, George Church

Services & Products

Development of tissue targeting therapies
Research in computational genomics and immunology
Disease and functional immunology research

Target Customers

Biotech and pharmaceutical companies Research institutions Healthcare providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $130.00K 1
Y Combinator
Y Combinator
01 Sep 2022
Support Program Undisclosed 1
Y Combinator
Y Combinator
01 Jun 2022

Eugit Therapeutics Alternatives & Competitors

View All Alternatives
Eugit Therapeutics vs
Alumis
Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C
249 employees
Biotechnology, Health Care
Eugit Therapeutics vs
Granza Bio
Granza Bio

Reprogramming Immunity for Target-Specific Medicines

Seed
7 employees
Biopharma, Biotechnology
Eugit Therapeutics vs
Aro Biotherapeutics
Aro Biotherapeutics United States

Series B
51 employees
Biotechnology, Health Care
Also compare with: Eugit Therapeutics vs Orbit Discovery Orbit Discovery View all alternatives

FAQ About Eugit Therapeutics

Tissue targeting of therapies
Eugit Therapeutics was founded in 2022.
Eugit Therapeutics is headquartered in San Carlos, United States.
Eugit Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Tissue Targeting Therapies, Immune System, Drug Discovery and Immune-Mediated Diseases. Its customers include Biotech and pharmaceutical companies, Research institutions and Healthcare providers.
Eugit Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing, Service Fee and Project Based.
Eugit Therapeutics has approximately 2 employees.
Eugit Therapeutics has completed 2 funding rounds, raising a total of $130.00K. The latest funding stage is Seed.
Eugit Therapeutics offers: Development of tissue targeting therapies, Research in computational genomics and immunology, Disease and functional immunology research.
Top alternatives and competitors to Eugit Therapeutics include Alumis, Granza Bio, Aro Biotherapeutics, Orbit Discovery, Parallel Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Eugit Therapeutics and Alumis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Eugit Therapeutics, https://bouncewatch.com/company/eugit-therapeutics, updated 26 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes